Synthesis of Cis-Diammine (1,1-cyclobutane dicarboxylate) Platinum(II)

Document Type : Research Note

Authors

School of Chemistry, University College of Science, University of Tehran, Tehran, I.R. IRAN

Abstract

Platinum-based anticancer drugs are chemotherapeutic agents to treat cancer. Carboplatin (cis diammine cyclobutane dicarboxylate platinum (II)) is a second generation drug that has less toxic than cisplatin, allowing for high dosages. In the first stage, 1,3-Cyclobutane dicarboxylic acid, a key intermediate for the preparation of carboplatin, have been synthesized in good yields using different methodology to achieve high purity then carboplatin was synthesized from the reaction of the prepared ligand with cisplatin. Purity of prepared carboplatin was confirmed by High-Performance Liquid Chro­matography (HPLC). Platinum(II) complex carboplatin,have been characterized with  1H and 13C nuclear magnetic resonance spectra and infrared spectroscopy.
 
 

Keywords

Main Subjects

References

[1] Morris M., Eifel P.J., Lu J., Grigsby P.W., Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer, N. Engl. J. Med., 340: 1137-1143(1999).
[2] Rose P., Bund B.N., Watkis E.B., Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma, N. Engl. J. Med.,340: 1154-1161(1999).
[3] Loehrer P.J., Einhorn L.H., Cisplatin., Ann. Itern. Med., 100: 7 04-713(1984).
[4] Wong E., Giandomenico C.M.,Current Status of Platinum-Based Antitumor Drugs, Chem. Rev., 99: 2451-2466 (1999).
[5] Kidani Y., Inagaki K., Iigo M., Hoshi A., Kuretani K., Antitumor Activity of 1,2-Diaminocyclohexaneplatinum Complexes Against Sarcoma-180 Ascites Form, J. Med. Chem., 21: 1315-1318(1978).
[6] Galanski M., Jakupec M.A., Keppler B.K., Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches, Curr.Med. Chem., 12: 2075-2094(2005).
[7] Kelland L., The Resurgence of Platinum-Based Cancer Chemotherapy, Nat. Rev. Cancer., 7: 573-584(2007).
[8] Wheate N.J., Walker S.., Craiga G.E., Ouna R., The Status of Platinum Anticancer Drugs in the Clinic and in Clinical Trials, Dalton Trans., 39 :8113-8127 (2010).
[9] Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., Fojo T., Oxaliplatin, Tetraplatin, Cisplatin, and Carboplatin: Spectrum of Activity in Drug-Resistant Cell Lines and in the Cell Lines of the National Cancer Institute's Anticancer Drug Screen Panel, Biochem. Pharmacol., 52: 1855-1865(1996).
[10] Knox R.J., Friedlos F., Lydall D.A., Roberts J., Mechanism of Cytotoxicity of Anticancer Platinum Drugs: Evidence That cis-Diamminedichloroplatinum(II) and cis-Diammine-(1,1-cyclobutanedicarboxylato)platinum(II) Differ Only in the Kinetics of Their Interaction with DNA, Cancer Res, 46: 1972-1979(1986).
[11] Alcindor T., Beauger N., Drug Development in Contemporary Oncology Oxaliplatin: a Review in the Era of Molecularly Targeted Therapy, Curr. Oncol., 18: 126-136 (2011).
[12] Ibrahim A., Hirschfeld S., Cohen M.H., Griebel D.J., Williams G.A., Pazdur R., FDA Drug Approval Summaries: Oxaliplatin, Oncologist, 9: 8-12(2004).
[13] Raymond E., Chaney S.G., Taamma A., Cvitkovic E., Oxaliplatin: A Review of Preclinical and Clinical Studies, Ann. Oncol., 9:1053-1071(1998). 

Files

Share

How to cite

Statistics